Effects of Acute and Chronic Empagliflozin Heart Failure

Summary

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.

Timeline

Start

2023-08-04

Primary completion

2026-05-08

Completion

2026-08-14

Drugs

Indications